Orange

Researchers are evaluating the effectiveness of MISSION, a multi-component team approach combined with medication for opioid use disorder (MOUD), compared to MOUD alone in people with co-occurring opioid use and mental health disorders (COD). This 4-year, 5-arm randomized control trial in Massachusetts will enroll 1,000 adults with COD to examine the benefits of MISSION or its parts plus MOUD on treatment engagement, substance use, and mental health outcomes. The study also aims to understand the mechanisms behind MISSION's effects and its cost-effectiveness. Participants will be randomly assigned to one of five groups: MOUD alone; full MISSION plus MOUD; or one of three combinations of two MISSION components plus MOUD. MISSION includes Critical Time Intervention (CTI), Dual Recovery Therapy (DRT), and Peer Support (PS). This team-based, time-limited treatment lasts 6 months and integrates psychosocial therapy with assertive outreach to help clients engage in care and recovery services. After treatment, participants will be followed for an additional year. During the study, researchers will assess engagement in treatment, medication adherence, substance use through self-report and drug screening, and mental health symptoms including PTSD, psychiatric severity, and suicide risk at multiple time points up to 12 months. They will also measure recovery capital, therapeutic alliance, health functioning, chronic pain, and motivation for treatment. Data collection includes baseline and follow-up interviews, questionnaires, and drug tests to monitor progress and safety throughout participation.